Alfuzosin
 | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 49% |
| Protein binding | 82%-90% |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Elimination half-life | 10 hours |
| Excretion | Fecal (69%) and renal (24%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C19H27N5O4 |
| Molar mass | 389.449 g/mol |
|
WikiDoc Resources for Alfuzosin |
|
Articles |
|---|
|
Most recent articles on Alfuzosin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Alfuzosin at Clinical Trials.gov Clinical Trials on Alfuzosin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Alfuzosin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Alfuzosin Discussion groups on Alfuzosin Directions to Hospitals Treating Alfuzosin Risk calculators and risk factors for Alfuzosin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Alfuzosin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Alfuzosin (patient information)
Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.
Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.
Side effects
The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.
Contraindications
Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation or to patients who are taking medications known to prolong the QT interval.